Asset Details
Do you wish to reserve the book?
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
Do you wish to request the book?
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
2006
Overview
Unfractionated heparin and low-molecular-weight heparins are often used to treat acute coronary syndromes. In this study, the pentasaccharide fondaparinux was found to have efficacy equal to that of enoxaparin in terms of anti-ischemic benefits but was associated with substantially less bleeding and lower long-term morbidity and mortality.
Fondaparinux was found to have efficacy equal to that of enoxaparin in terms of anti-ischemic benefits but was associated with substantially less bleeding and lower long-term morbidity and mortality.
The combined use of anticoagulants,
1
antiplatelet agents,
2
–
4
and an invasive strategy
5
in high-risk patients with acute coronary syndromes reduces ischemic coronary events but also increases bleeding. Bleeding may increase the risk of death,
6
myocardial infarction, and stroke. Therefore, future therapies should either preserve or enhance benefits without increasing bleeding. Unfractionated heparin and low-molecular-weight heparins are commonly used in patients with acute coronary syndromes, but enoxaparin may be modestly superior to unfractionated heparin in reducing the risk of death or myocardial infarction.
7
Fondaparinux (Arixtra, GlaxoSmithKline), a synthetic pentasaccharide, selectively binds antithrombin and causes rapid and predictable inhibition of factor Xa. . . .
Publisher
Massachusetts Medical Society
Subject
/ Angina, Unstable - drug therapy
/ Angina, Unstable - mortality
/ Angioplasty, Balloon, Coronary
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Anticoagulants/adverse effects/therapeutic use
/ Biological and medical sciences
/ Enoxaparin - adverse effects
/ Enoxaparin - therapeutic use
/ Enoxaparin/adverse effects/therapeutic use
/ Female
/ Heart
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ MEDICIN
/ MEDICINE
/ Myocardial Infarction - drug therapy
/ Myocardial Infarction - mortality
/ Myocardial Infarction - therapy
/ Myocardial Infarction/drug therapy/mortality/therapy
/ Polysaccharides - adverse effects
/ Polysaccharides - therapeutic use
/ Polysaccharides/adverse effects/therapeutic use
/ Stroke
